Sign in Register

Cefdinir (cefdinir)

Advertisement

Last reviewed · Source: First Databank (FDB) drug data

Overview

Cefdinir is a semisynthetic, third generation cephalosporin antibiotic.

Cefdinir is used orally for the treatment of mild to moderate upper and lower respiratory tract infections (i.e., acute maxillary sinusitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia) caused by susceptible bacteria. The drug also is used orally for the treatment of acute bacterial otitis media, streptococcal pharyngitis and tonsillitis, and mild to moderate, uncomplicated skin and skin structure infections caused by susceptible bacteria.

Generic name: cefdinir
Pronunciation: (SEFF-dih-neer)

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Cefdinir

Intelligence content is not available yet.

Indications

The following indications are listed for Cefdinir:

  • Acute Bacterial Otitis Media
  • Acute Maxillary Haemophilus Influenzae Sinusitis
  • Acute Maxillary Moraxella Catarrhalis Sinusitis
  • Acute Maxillary Streptococcus Pneumoniae Sinusitis
  • Haemophilus Influenzae Bronchitis
  • Haemophilus Influenzae Pneumonia
  • Haemophilus Parainfluenza Pneumonia
  • Haemophilus Parainfluenzae Bronchitis
  • Moraxella Catarrhalis Bronchitis
  • Moraxella Catarrhalis Pneumonia
  • Pharyngitis Due To Streptococcus Pyogenes
  • Skin And Skin Structure Streptococcus Pyogenes Infection
  • Staphylococcus Aureus Skin And Skin Structure Infection
  • Streptococcal Pneumonia
  • Streptococcus Pneumoniae Bronchitis
  • Tonsillitis Due To Streptococcus Pyogenes

Also known as: Acute Maxillary Sinusitis Due To B. Catarrhalis, Acute Maxillary Sinusitis Due To Branhamella Catarrhalis, Acute Maxillary Sinusitis Due To Diplococcus Pneumoniae, Acute Maxillary Sinusitis Due To Fraenkel's Pneumococcus, Acute Maxillary Sinusitis Due To H. Flu, Acute Maxillary Sinusitis Due To Haemophilus Influenzae, Acute Maxillary Sinusitis Due To Hemophilus Influenzae, Acute Maxillary Sinusitis Due To Influenza Bacillus, Acute Maxillary Sinusitis Due To Moraxella Catarrhalis, Acute Maxillary Sinusitis Due To Neisseria Catarrhalis, Acute Maxillary Sinusitis Due To Pfeiffer's Bacillus, Acute Maxillary Sinusitis Due To Pneumococcus, Acute Maxillary Sinusitis Due To Pneumonococcus, Acute Maxillary Sinusitis From Streptococcus Pneumoniae, Bacterial Otitis Media, Bronchitis Due To B. Catarrhalis, Bronchitis Due To Branhamella Catarrhalis, Bronchitis Due To Diplococcus Pneumoniae, Bronchitis Due To Fraenkel's Pneumococcus, Bronchitis Due To Fraenkel-Weichselbaum Pneumococcus, Bronchitis Due To H. Flu, Bronchitis Due To H. Influenzae, Bronchitis Due To Haemophilus Influenzae, Bronchitis Due To Haemophilus Parainfluenzae, Bronchitis Due To Hemophilus Influenzae, Bronchitis Due To Hemophilus Parainfluenzae, Bronchitis Due To Influenzae Bacillus, Bronchitis Due To M. Catarrhalis, Bronchitis Due To Moraxella Catarrhalis, Bronchitis Due To Neisseria Catarrhalis, Bronchitis Due To Pfeiffer's Bacillus, Bronchitis Due To Pneumococcus, Bronchitis Due To Pneumonococcus, Bronchitis Due To Streptococcus Pneumoniae, Epidemic Sore Throat, H. Flu Pneumonia, H. Influenzae Pneumonia, Hemophilus Influenzae Pneumonia, Influenza Bacillus Pneumonia, Pfeiffer's Bacillus Pneumonia, Pharyngitis Due To Group A Beta-Hemolytic Streptococci, Pharyngitis Due To Streptococcus Epidemicus, Pneumonia Due To B. Catarrhalis, Pneumonia Due To Branhamella Catarrhalis, Pneumonia Due To Haemophilus Influenzae, Pneumonia Due To Haemophilus Parainfluenzae, Pneumonia Due To Hemophilus Parainfluenzae, Pneumonia Due To M. Catarrhalis, Pneumonia Due To Moraxella Catarrhalis, Pneumonia Due To Neisseria Catarrhalis, Pneumonia Due To Streptococcus Species, Pneumonia Due To Streptococcus Spp., Septic Sore Throat, Skin & Skin Soft Tissue Streptococcus Pyogenes Infection, Skin And Skin Soft Tissue Staphylococcus Aureus Infection, Streptococcal Pharyngitis, Streptococcus Pyogenes Tonsillitis.

Dosing

Patients with creatinine clearances of 30 mL/minute or greater may receive the usual dosage of cefdinir.

Adults with creatinine clearances less than 30 mL/minute should receive cefdinir in a dosage of 300 mg once daily and children with creatinine clearances less than 30 mL/minute per 1.73 m2 should receive the drug in a dosage of 7 mg/kg (up to 300 mg) once daily.

For patients maintained on long-term hemodialysis, the usual initial dosage of cefdinir is 300 mg every 48 hours for adults or 7 mg/kg (up to 300 mg) every 48 hours for children. Because cefdinir is partially removed by hemodialysis, a supplemental dose of cefdinir (300 mg in adults or 7 mg/kg in children) should be given at the end of each dialysis period and subsequent doses administered every 48 hours.

While the pharmacokinetics of cefdinir have not been studied in patients with hepatic impairment, hepatic metabolism of the drug is negligible and the manufacturer states that dosage adjustments are not expected to be necessary in such patients.

Drug interactions

There is no enhanced messaging for this drug.

Contraindications

There is no enhanced messaging for this drug.

Adverse reactions

There is no enhanced messaging for this drug.

Precautions

No enhanced messaging available.

ICD codes

No ICD codes are available for this drug.

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a 5-digit ZIP code. Searching does not change your profile.

Enter a ZIP code to view available health plans.

Last reviewed · Source: First Databank (FDB) drug data